HC Wainwright Research Analysts Boost Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for Day One Biopharmaceuticals in a research note issued on Wednesday, April 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.79) for the year, up from their previous estimate of ($2.80). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.87 EPS.

Several other brokerages also recently commented on DAWN. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Needham & Company LLC boosted their target price on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $13.60 on Friday. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $17.85. The company’s 50 day moving average price is $15.23 and its two-hundred day moving average price is $13.79. The company has a market capitalization of $1.19 billion, a PE ratio of -5.71 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Insider Buying and Selling

In related news, CFO Charles N. York II sold 2,666 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at approximately $18,818,085.24. The disclosure for this sale can be found here. Insiders have sold a total of 55,781 shares of company stock worth $883,160 in the last quarter. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Arizona State Retirement System increased its position in shares of Day One Biopharmaceuticals by 8.8% during the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after purchasing an additional 995 shares during the last quarter. Quintet Private Bank Europe S.A. grew its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after purchasing an additional 1,262 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Day One Biopharmaceuticals by 9.7% in the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock worth $218,000 after purchasing an additional 1,569 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.